Facebook Instagram Tiktok Yelp Youtube
Begin Your Journey
Book Now

Ipamorelin

Supporting Your Body’s Natural Growth Pathways

Recovery, body composition, and long-term performance aren’t just about effort — they’re influenced by how your body regulates hormones, repair, and adaptation.

At Radiant You, we use targeted therapies like ipamorelin to support your body’s natural growth hormone signaling in a thoughtful, controlled way.

Begin Your Journey

Why We’re Providing You This Information

At Radiant You, we believe you deserve to understand the science behind your care. This
overview explains how ipamorelin works, what it’s designed to support, and how we approach its use safely and responsibly.

Begin Your Journey

What Is Ipamorelin?

Ipamorelin is a peptide that stimulates your body to release its own growth hormone (GH).
When growth hormone is released, it increases levels of IGF-1, a key hormone involved in:
  • Muscle maintenance
  • Fat metabolism
  • Recovery
  • Tissue repair

Ipamorelin belongs to a class called growth hormone secretagogues, meaning it encourages your body to produce hormone naturally rather than replacing it.

It is not FDA-approved and is prescribed off-label through compounding
pharmacies.

How It Works
Ipamorelin mimics a natural hormone called ghrelin.
  • Binds to receptors in the pituitary gland
  • Triggers a controlled pulse of growth hormone
  • Peaks ~40 minutes after injection
  • Duration ~2 hours
Unlike some similar compounds, it does not significantly increase cortisol, making it more selective.
Begin Your Journey
How It’s Different from Sermorelin
Both therapies support growth hormone release — but through different pathways.
Sermorelin
  • Mimics natural growth hormone–releasing hormone (GHRH)
  • Short-acting
  • Previously FDA-approved (now discontinued)
Ipamorelin
  • Mimics ghrelin
  • Longer duration
  • More targeted receptor activity

Both aim to support physiologic hormone signaling, not override it.

What It May Help With

Because growth hormone plays a role in repair and metabolism, supporting this pathway may help with:
  • Recovery between workouts
  • Lean muscle maintenance
  • Body composition
  • Sleep quality
These benefits are based on known physiology, though:
Long-term outcome data specific to ipamorelin remain limited.

Safety and Monitoring

Ipamorelin is generally well tolerated in short-term studies.
Possible side effects include:
  • Injection site reactions
  • Headache
  • Flushing
  • Dizziness
  • Increased hunger
Because it influences growth hormone and IGF-1 levels, monitoring is important to maintain safe, physiologic ranges.
Who May Not Be a Candidate
This therapy may not be appropriate if you have:
  • Active or prior cancer
  • Pituitary disorders
  • Poorly controlled diabetes
  • Pregnancy or breastfeeding
A full medical evaluation is required before starting treatment.
Begin Your Journey

How This Fits Into Your Health

Ipamorelin is not a standalone solution.
It works best when combined with:
  • Strength training
  • Adequate sleep
  • Nutrition
  • Recovery strategies
And if those areas aren’t fully where you want them to be, that’s exactly where we can help — through a more comprehensive, personalized approach at Radiant You.
Begin Your Journey

Our Approach at Radiant You

We use ipamorelin selectively for patients interested in supporting:
  • Recovery
  • Performance
  • Body composition
Our approach focuses on:
  • Conservative dosing
  • Regular monitoring (including IGF-1)
  • Staying within physiologic ranges
If it supports your goals and you tolerate it well, we continue. If not, we reassess. Our goal is thoughtful optimization — not aggressive hormone elevation.

The Bottom Line

Ipamorelin is a targeted therapy designed to support your body’s natural growth hormone release.
  • Encourages physiologic hormone signaling
  • May support recovery, sleep, and body composition
  • Requires careful monitoring and individualized use

Sources & Further Reading

Mechanism of Action

  • Raun K et al. European Journal of Endocrinology. 1998 — demonstrated selective GH release without significant cortisol stimulation
  • Ghigo E et al. European Journal of Endocrinology. 1997 — reviewed growth hormone secretagogues and receptor pathways

Human Growth Hormone Response

Gobburu JV et al. Pharmaceutical Research. 1999 — showed predictable, dose- dependent GH release with ~2-hour half-life and peak response around 40 minutes

Comparison With Sermorelin

  • Prakash A et al. BioDrugs. 1999 — described sermorelin’s mechanism and clinical use
  • Esposito P et al. Advanced Drug Delivery Reviews. 2003 — detailed pharmacokinetics and short duration of sermorelin

Monitoring & Hormone Safety

  • Yuen KCJ et al. Endocrine Practice. 2019 — guidelines for growth hormone monitoring
  • Fleseriu M et al. Lancet Diabetes & Endocrinology. 2022 — IGF-1 interpretation using age- and sex-specific ranges
  • Clemmons DR. Pituitary. 2007 — variability in IGF-1 testing and importance of consistent monitoring
Instagram Facebook